Parameters critical for the effector mechanism of anti‐CD20 antibodies revisited
Open Access
- 7 February 2018
- journal article
- editorial
- Published by Wiley in British Journal of Haematology
- Vol. 180 (6), 777-779
- https://doi.org/10.1111/bjh.15130
Abstract
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.Keywords
Funding Information
- Narodowe Centrum Nauki (2014/14/E/NZ6/00182)
This publication has 19 references indexed in Scilit:
- Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer PatientsPublished by The American Association of Immunologists ,2012
- BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological propertiesInternational Journal of Oncology, 2011
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicityBlood, 2010
- Development of novel humanized anti‐CD20 antibodies based on affinity constant and epitopeCancer Science, 2009
- Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphomaBlood, 2009
- OfatumumabmAbs, 2009
- Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignanciesInvestigational New Drugs, 2009
- NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complementBlood, 2008
- Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular CytotoxicityClinical Cancer Research, 2006
- Antibody Elbow Angles are Influenced by their Light Chain ClassJournal of Molecular Biology, 2006